NASDAQ:SIENSientra Stock Price, Forecast & News

Sientra's stock was trading at $2.44 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, SIEN stock has increased by 54.9% and is now trading at $3.78. View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sientra in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Sientra.

Sientra is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Sientra.

Sientra Inc (NASDAQ:SIEN) announced its quarterly earnings results on Monday, May, 11th. The medical instruments supplier reported ($0.57) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.49) by $0.08. The medical instruments supplier earned $16.93 million during the quarter, compared to analysts' expectations of $18.70 million. Sientra had a negative net margin of 134.87% and a negative return on equity of 101.94%. View Sientra's earnings history.

Sientra issued an update on its FY 2020 After-Hours earnings guidance on Wednesday, March, 11th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $94-98 million, compared to the consensus revenue estimate of $101.66 million.

7 brokerages have issued 1-year target prices for Sientra's stock. Their forecasts range from $5.00 to $10.00. On average, they expect Sientra's share price to reach $7.05 in the next twelve months. This suggests a possible upside of 86.5% from the stock's current price. View analysts' price targets for Sientra.

News coverage about SIEN stock has been trending negative on Wednesday, according to InfoTrie. The research firm identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Sientra earned a daily sentiment score of -2.8 on InfoTrie's scale. They also gave news coverage about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutSientra.

Sientra saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 3,090,000 shares, an increase of 25.6% from the April 30th total of 2,460,000 shares. Based on an average trading volume of 1,430,000 shares, the days-to-cover ratio is presently 2.2 days. Approximately 7.2% of the company's stock are sold short. View Sientra's Current Options Chain.

Some companies that are related to Sientra include Establishment Labs (ESTA), Invacare (IVC), RTI Surgical (RTIX), Lakeland Industries (LAKE), ConforMIS (CFMS), COLLPLANT HOLDI/S (CLGN), Allied Healthcare Products (AHPI), Ocugen (OCGN), Histogenics (HSGX), Rewalk Robotics (RWLK), Bionik Laboratories (BNKL), Precision Therapeutics (POAI), NanoVibronix (NAOV) and Avitar (AVTI). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Sientra investors own include Micron Technology (MU), Oasis Petroleum (OAS), Advanced Micro Devices (AMD), Alibaba Group (BABA), Genocea Biosciences (GNCA), AT&T (T), Viking Therapeutics (VKTX), Verizon Communications (VZ), Anavex Life Sciences (AVXL) and salesforce.com (CRM).

Sientra trades on the NASDAQ under the ticker symbol "SIEN."

Sientra's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.44%), UBS Group AG (4.85%), Schroder Investment Management Group (3.80%), JPMorgan Chase & Co. (2.31%), Granahan Investment Management Inc. MA (1.62%) and State Street Corp (1.40%). Company insiders that own Sientra stock include Jeffrey M Nugent, Keith J Sullivan, Paul Sean Little and Timothy Haines. View institutional ownership trends for Sientra.

SIEN stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Bank of New York Mellon Corp, Deutsche Bank AG, Spark Investment Management LLC, BlackRock Inc., State Street Corp, Two Sigma Investments LP, and Blair William & Co. IL. View insider buying and selling activity for Sientra.

SIEN stock was purchased by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Nuveen Asset Management LLC, AQR Capital Management LLC, Granahan Investment Management Inc. MA, Geode Capital Management LLC, Los Angeles Capital Management & Equity Research Inc., SG Americas Securities LLC, and UBS Group AG. Company insiders that have bought Sientra stock in the last two years include Keith J Sullivan, and Paul Sean Little. View insider buying and selling activity for Sientra.

Shares of SIEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of SIEN stock can currently be purchased for approximately $3.78.

Sientra has a market capitalization of $189.12 million and generates $83.70 million in revenue each year. The medical instruments supplier earns $-106,820,000.00 in net income (profit) each year or ($2.29) on an earnings per share basis. Sientra employs 339 workers across the globe.

The official website for Sientra is www.sientra.com.

Sientra's mailing address is 420 SOUTH FAIRVIEW AVENUE SUITE 200, SANTA BARBARA CA, 93117. The medical instruments supplier can be reached via phone at 805-562-3500 or via email at [email protected]